Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of NX 1207 given over 3 months in patients with benign prostatic hyperplasia.

Next Previous
X
Search
Trial Profile

Phase II trial of NX 1207 given over 3 months in patients with benign prostatic hyperplasia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fexapotide (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Nymox Pharmaceutical Corporation

    • Most Recent Events

    • 22 Jun 2010 Results after 48-60 months of follow-up, assessing AUA BPH Symptom Index scores, reported in a Nymox Pharmaceutical Corporation media release.
    • 26 Sep 2008 Results from this development program presented at the American Urological Association Meeting in Chicago, as reported in a Nymox media release.
    • 27 Sep 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top